Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지
DOI QR코드

DOI QR Code

Recipient Management before Lung Transplantation

  • Kim, Hyoung Soo (Department of Cardiothoracic Surgery, Allergy and Critical Care Medicine, Hallym University Sacred Heart Hospital) ;
  • Park, Sunghoon (Department of Pulmonary, Allergy and Critical Care Medicine, Hallym University Sacred Heart Hospital)
  • Received : 2022.06.20
  • Accepted : 2022.07.18
  • Published : 2022.08.05
Download PDF
⟨ Previous Next ⟩

Abstract

Lung transplantation is considered a viable treatment option for patients with end-stage lung disease. Recent decades have seen a gradual increase in the number of lung transplantation patients worldwide, and in South Korea, the case number has increased at least 3-fold during the last decade. Furthermore, the waiting list time is becoming longer, and more elderly patients (>65 years) are undergoing lung transplantation; that is, the patients placed on the waiting list are older and sicker than in the past. Hence, proper management during the pre-transplantation period, as well as careful selection of candidates, is a key factor for transplant success and patient survival. Although referring and transplant centers should address many issues, the main areas of focus should be the timing of referral, nutrition, pulmonary rehabilitation, critical care (including mechanical ventilation and extracorporeal membrane oxygenation), psychological support, and the management of preexisting comorbid conditions (coronary artery disease, diabetes mellitus, gastroesophageal reflux disease, osteoporosis, malignancy, viral infections, and chronic infections). In this context, the present article reviews and summarizes the pre-transplantation management strategies for adult patients listed for lung transplantation.

Keywords

Acknowledgement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

  1. Adegunsoye A, Strek ME, Garrity E, Guzy R, Bag R. Comprehensive care of the lung transplant patient. Chest 2017;152:150-64. https://doi.org/10.1016/j.chest.2016.10.001
  2. International Society for Heart and Lung Transplantation. International Thoracic Organ Transplant (TTX) Registry data slides [Internet]. Chicago (IL): International Society for Heart and Lung Transplantation; 2021 [cited 2022 Jun 1]. Available from: https://ishltregistries.org/registries/slides.asp?yearToDisplay=2021.
  3. The National Institute of Organ, Tissue and Blood Management. Annual report for 2019 [Internet]. Seoul: The National Institute of Organ, Tissue and Blood Management; 2020 [cited 2022 Jun 1]. Available from: https://www.konos.go.kr/board/boardListPage.do?page=sub4_2_1&boardId=30.
  4. Korea Organ Donation Agency. Current status of donation after brain death [Internet]. Seoul: Korea Organ Donation Agency; 2022 [cited 2022 Jun 1]. Available from: https://www.koda1458.kr/info/transplant.do.
  5. Leard LE, Holm AM, Valapour M, et al. Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2021;40:1349-79. https://doi.org/10.1016/j.healun.2021.07.005
  6. Young KA, Dilling DF. The future of lung transplantation. Chest 2019;155:465-73. https://doi.org/10.1016/j.chest.2018.08.1036
  7. Kanasky WF Jr, Anton SD, Rodrigue JR, Perri MG, Szwed T, Baz MA. Impact of body weight on long-term survival after lung transplantation. Chest 2002;121:401-6. https://doi.org/10.1378/chest.121.2.401
  8. Lederer DJ, Wilt JS, D'Ovidio F, et al. Obesity and underweight are associated with an increased risk of death after lung transplantation. Am J Respir Crit Care Med 2009;180:887-95. https://doi.org/10.1164/rccm.200903-0425OC
  9. Lederer DJ, Kawut SM, Wickersham N, et al. Obesity and primary graft dysfunction after lung transplantation: the Lung Transplant Outcomes Group Obesity Study. Am J Respir Crit Care Med 2011;184:1055-61. https://doi.org/10.1164/rccm.201104-0728OC
  10. Singer JP, Peterson ER, Snyder ME, et al. Body composition and mortality after adult lung transplantation in the United States. Am J Respir Crit Care Med 2014;190:1012-21. https://doi.org/10.1164/rccm.201405-0973OC
  11. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-12. https://doi.org/10.1056/NEJMoa021322
  12. Snell GI, Bennetts K, Bartolo J, et al. Body mass index as a predictor of survival in adults with cystic fibrosis referred for lung transplantation. J Heart Lung Transplant 1998;17:1097-103.
  13. Halloran K, Snell GI. Adipose tissue characterization and primary lung graft dysfunction. J Heart Lung Transplant 2019;38:1257-8. https://doi.org/10.1016/j.healun.2019.09.015
  14. Hamilton BC, Kukreja J, Ware LB, Matthay MA. Protein biomarkers associated with primary graft dysfunction following lung transplantation. Am J Physiol Lung Cell Mol Physiol 2017;312:L531-41. https://doi.org/10.1152/ajplung.00454.2016
  15. Woodman CL, Geist LJ, Vance S, Laxson C, Jones K, Kline JN. Psychiatric disorders and survival after lung transplantation. Psychosomatics 1999;40:293-7. https://doi.org/10.1016/S0033-3182(99)71221-1
  16. Chacko RC, Harper RG, Kunik M, Young J. Relationship of psychiatric morbidity and psychosocial factors in organ transplant candidates. Psychosomatics 1996;37:100-7. https://doi.org/10.1016/S0033-3182(96)71575-X
  17. Parekh PI, Blumenthal JA, Babyak MA, et al. Psychiatric disorder and quality of life in patients awaiting lung transplantation. Chest 2003;124:1682-8. https://doi.org/10.1378/chest.124.5.1682
  18. Shah AS, Nwakanma L, Simpkins C, Williams J, Chang DC, Conte JV. Pretransplant panel reactive antibodies in human lung transplantation: an analysis of over 10,000 patients. Ann Thorac Surg 2008;85:1919-24. https://doi.org/10.1016/j.athoracsur.2008.02.011
  19. Weston M, Rolfe M, Haddad T, Lopez-Cepero M. Desensitization protocol using bortezomib for highly sensitized patients awaiting heart or lung transplants. Clin Transpl 2009:393-9.
  20. Snyder LD, Gray AL, Reynolds JM, et al. Antibody desensitization therapy in highly sensitized lung transplant candidates. Am J Transplant 2014;14:849-56. https://doi.org/10.1111/ajt.12636
  21. Ju L, Suberbielle C, Li X, Mooney N, Charron D. HLA and lung transplantation. Front Med 2019;13:298-313. https://doi.org/10.1007/s11684-018-0636-x
  22. Maxwell BG, Levitt JE, Goldstein BA, et al. Impact of the lung allocation score on survival beyond 1 year. Am J Transplant 2014;14:2288-94. https://doi.org/10.1111/ajt.12903
  23. Lee JG, Park MS, Jeong SJ, et al. Critical care before lung transplantation. Acute Crit Care 2018;33:197-205. https://doi.org/10.4266/acc.2018.00367
  24. Bermudez CA, Rocha RV, Zaldonis D, et al. Extracorporeal membrane oxygenation as a bridge to lung transplant: midterm outcomes. Ann Thorac Surg 2011;92:1226-32. https://doi.org/10.1016/j.athoracsur.2011.04.122
  25. Fuehner T, Kuehn C, Hadem J, et al. Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. Am J Respir Crit Care Med 2012;185:763-8. https://doi.org/10.1164/rccm.201109-1599OC
  26. Lang G, Taghavi S, Aigner C, et al. Primary lung transplantation after bridge with extracorporeal membrane oxygenation: a plea for a shift in our paradigms for indications. Transplantation 2012;93:729-36. https://doi.org/10.1097/TP.0b013e318246f8e1
  27. Myaskovsky L, Dew MA, McNulty ML, et al. Trajectories of change in quality of life in 12-month survivors of lung or heart transplant. Am J Transplant 2006;6:1939-47. https://doi.org/10.1111/j.1600-6143.2006.01395.x
  28. Rozenberg D, Wickerson L, Singer LG, Mathur S. Sarcopenia in lung transplantation: a systematic review. J Heart Lung Transplant 2014;33:1203-12. https://doi.org/10.1016/j.healun.2014.06.003
  29. Smeritschnig B, Jaksch P, Kocher A, et al. Quality of life after lung transplantation: a cross-sectional study. J Heart Lung Transplant 2005;24:474-80. https://doi.org/10.1016/j.healun.2003.12.013
  30. Langer D. Rehabilitation in patients before and after lung transplantation. Respiration 2015;89:353-62. https://doi.org/10.1159/000430451
  31. Florian J, Rubin A, Mattiello R, Fontoura FF, Camargo Jde J, Teixeira PJ. Impact of pulmonary rehabilitation on quality of life and functional capacity in patients on waiting lists for lung transplantation. J Bras Pneumol 2013;39:349-56. https://doi.org/10.1590/S1806-37132013000300012
  32. Gloeckl R, Halle M, Kenn K. Interval versus continuous training in lung transplant candidates: a randomized trial. J Heart Lung Transplant 2012;31:934-41. https://doi.org/10.1016/j.healun.2012.06.004
  33. Jastrzebski D, Ochman M, Ziora D, et al. Pulmonary rehabilitation in patients referred for lung transplantation. Adv Exp Med Biol 2013;755:19-25. https://doi.org/10.1007/978-94-007-4546-9_3
  34. Rochester CL, Fairburn C, Crouch RH. Pulmonary rehabilitation for respiratory disorders other than chronic obstructive pulmonary disease. Clin Chest Med 2014;35:369-89. https://doi.org/10.1016/j.ccm.2014.02.016
  35. Koprivanac M, Budev MM, Yun JJ, et al. How important is coronary artery disease when considering lung transplant candidates? J Heart Lung Transplant 2016;35:1453-61. https://doi.org/10.1016/j.healun.2016.03.011
  36. Chaikriangkrai K, Jyothula S, Jhun HY, et al. Impact of pre-operative coronary artery disease on cardiovascular events following lung transplantation. J Heart Lung Transplant 2016;35:115-21. https://doi.org/10.1016/j.healun.2015.08.009
  37. Makey IA, Sui JW, Huynh C, Das NA, Thomas M, Johnson S. Lung transplant patients with coronary artery disease rarely die of cardiac causes. Clin Transplant 2018;32:e13354. https://doi.org/10.1111/ctr.13354
  38. Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014: an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015;34:1-15. https://doi.org/10.1016/j.healun.2014.06.014
  39. Hackman KL, Bailey MJ, Snell GI, Bach LA. Diabetes is a major risk factor for mortality after lung transplantation. Am J Transplant 2014;14:438-45. https://doi.org/10.1111/ajt.12561
  40. Riou M, Renaud-Picard B, Munch M, et al. Organized management of diabetes mellitus in lung transplantation: study of glycemic control and patient survival in a single center. Transplant Proc 2019;51:3375-84. https://doi.org/10.1016/j.transproceed.2019.07.019
  41. Young LR, Hadjiliadis D, Davis RD, Palmer SM. Lung transplantation exacerbates gastroesophageal reflux disease. Chest 2003;124:1689-93. https://doi.org/10.1378/chest.124.5.1689
  42. Biswas Roy S, Elnahas S, Serrone R, et al. Early fundoplication is associated with slower decline in lung function after lung transplantation in patients with gastroesophageal reflux disease. J Thorac Cardiovasc Surg 2018;155:2762-71. https://doi.org/10.1016/j.jtcvs.2018.02.009
  43. CONGRESS.GOV. HIV Organ Policy Equity Act [Internet]. Washington (DC): CONGRESS.GOV; 2013 [cited 2022 Jun 5]. Available from: https://www.congress.gov/bill/113th-congress/senate-bill/330.
  44. Englum BR, Ganapathi AM, Speicher PJ, et al. Impact of donor and recipient hepatitis C status in lung transplantation. J Heart Lung Transplant 2016;35:228-35. https://doi.org/10.1016/j.healun.2015.10.012
  45. Belli LS, Perricone G, Adam R, et al. Impact of DAAs on liver transplantation: major effects on the evolution of indications and results: an ELITA study based on the ELTR registry. J Hepatol 2018;69:810-7. https://doi.org/10.1016/j.jhep.2018.06.010
  46. Abdelbasit A, Hirji A, Halloran K, et al. Lung transplantation from hepatitis C viremic donors to uninfected recipients. Am J Respir Crit Care Med 2018;197:1492-6. https://doi.org/10.1164/rccm.201712-2614le
  47. Woolley AE, Singh SK, Goldberg HJ, et al. Heart and lung transplants from HCV-infected donors to uninfected recipients. N Engl J Med 2019;380:1606-17. https://doi.org/10.1056/NEJMoa1812406
  48. Beaty CA, George TJ, Kilic A, Conte JV, Shah AS. Pre-transplant malignancy: an analysis of outcomes after thoracic organ transplantation. J Heart Lung Transplant 2013;32:202-11. https://doi.org/10.1016/j.healun.2012.11.003
  49. Al-Adra DP, Hammel L, Roberts J, et al. Pretransplant solid organ malignancy and organ transplant candidacy: a consensus expert opinion statement. Am J Transplant 2021;21:460-74. https://doi.org/10.1111/ajt.16318
  50. Al-Adra DP, Hammel L, Roberts J, et al. Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: a consensus expert opinion statement. Am J Transplant 2021;21:475-83. https://doi.org/10.1111/ajt.16324
  51. Elnahas S, Olson MT, Kang P, et al. Factors associated with skin cancer in lung transplant recipients: a single-center experience. Clin Transplant 2019;33:e13718.
  52. Arjuna A, Olson MT, Walia R. Current trends in candidate selection, contraindications, and indications for lung transplantation. J Thorac Dis 2021;13:6514-27. https://doi.org/10.21037/jtd-2021-09
  53. Weill D. Lung transplantation: indications and contraindications. J Thorac Dis 2018;10:4574-87. https://doi.org/10.21037/jtd.2018.06.141
  54. Starr SP. Immunology update: long-term care of solid organ transplant recipients. FP Essent 2016;450:22-7.
  55. Cairoli E, Eller-Vainicher C, Morlacchi LC, et al. Bone involvement in young adults with cystic fibrosis awaiting lung transplantation for end-stage respiratory failure. Osteoporos Int 2019;30:1255-63. https://doi.org/10.1007/s00198-019-04893-z
  56. Kotloff RM, Zuckerman JB. Lung transplantation for cystic fibrosis: special considerations. Chest 1996;109:787-98. https://doi.org/10.1378/chest.109.3.787
  57. Chalermskulrat W, Sood N, Neuringer IP, et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006;61:507-13. https://doi.org/10.1136/thx.2005.049247
  58. Husain S, Sole A, Alexander BD, et al. The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: executive summary. J Heart Lung Transplant 2016;35:261-82. https://doi.org/10.1016/j.healun.2016.01.007
  59. Ramos KJ, Smith PJ, McKone EF, et al. Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines. J Cyst Fibros 2019;18:321-33. https://doi.org/10.1016/j.jcf.2019.03.002
  60. Saiman L, Mehar F, Niu WW, et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 1996;23:532-7. https://doi.org/10.1093/clinids/23.3.532
  61. Dobbin C, Maley M, Harkness J, et al. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J Hosp Infect 2004;56:277-82. https://doi.org/10.1016/j.jhin.2004.01.003
  62. Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 2006;73:27-33. https://doi.org/10.1159/000087686
  63. Hadjiliadis D, Steele MP, Chaparro C, et al. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant 2007;26:834-8. https://doi.org/10.1016/j.healun.2007.05.018